A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)
Impaired cardiovascular function or clinically significant cardiovascular diseases
Stem cell transplant within 12 weeks prior to enrollment or active graft vs host disease
Participants with any active, uncontrolled bacterial, fungal, or viral infection
Any other active malignancy within 3 years prior to enrollment, except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ
Previous treatment with:
BCMA-directed or CD3 redirecting therapy
Iberdomide (CC-220) or Mezigdomide
Administration of strong inhibitor or inducer of CYP3A4/5 within 2 weeks prior to dosing and during the study
Administration with an investigational product within 30 days preceding the first dose of study intervention
Participant is unable or unwilling to undergo protocol required thromboembolism prophylaxis
Clareo Health | A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)
